ํBV3 โข FRA
add
Bavarian Nordic A/S
์ ์ผ ์ข
๊ฐ
โฌ24.23
์ผ์ผ ๋ณ๋ํญ
โฌ24.04 - โฌ24.80
52์ฃผ ๋ณ๋ํญ
โฌ17.81 - โฌ42.70
์๊ฐ์ด์ก
22.35์ต USD
ํ๊ท ๊ฑฐ๋๋
424.00
์ฃผ๊ฐ์์ต๋ฅ
-
๋ฐฐ๋น์์ต๋ฅ
-
๊ธฐ๋ณธ ๊ฑฐ๋์
CPH
์์ฅ ๋ด์ค
์ฌ๋ฌด
์์ต๊ณ์ฐ์
์์ต
์์ด์ต
| (DKK) | 2025๋ 3์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
์์ต | 13.47์ต | 61.95% |
์ด์๋น | 4.22์ต | 7.01% |
์์ด์ต | 2.19์ต | 291.14% |
์์ด์ต๋ฅ | 16.25 | 218.10% |
์ฃผ๋น ์์ต | โ | โ |
EBITDA | 4.20์ต | 1,821.18% |
์ ํจ ์ธ์จ | 4.70% | โ |
๋์ฐจ๋์กฐํ
์ด์์ฐ
์ด๋ถ์ฑ
| (DKK) | 2025๋ 3์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
ํ๊ธ ๋ฐ ๋จ๊ธฐ ํฌ์ | 12.36์ต | -46.10% |
์ด์์ฐ | 135.53์ต | -0.50% |
์ด๋ถ์ฑ | 19.97์ต | -42.07% |
์ด์๊ธฐ์๋ณธ | 115.56์ต | โ |
๋ฐํ ์ฃผ์ | 7783.95๋ง | โ |
์ฃผ๊ฐ์์์ฐ๋น์จ | 0.16 | โ |
์ด์์ฐ์ด์ต๋ฅ | 4.63% | โ |
์๋ณธ์ด์ต๋ฅ | 5.58% | โ |
ํ๊ธ ํ๋ฆ
์ํ๊ธํ๋ฆ
| (DKK) | 2025๋ 3์info | ์ ๋ ๋๋น ๋ณ๋ |
|---|---|---|
์์ด์ต | 2.19์ต | 291.14% |
์์
ํ๊ธ ํ๋ฆ | -3.87์ต | -188.93% |
ํฌ์ ํ๊ธ ํ๋ฆ | -3.73์ต | 64.29% |
์๊ธ ์กฐ๋ฌ ํ๊ธ ํ๋ฆ | -1.61์ต | -1,400.76% |
์ํ๊ธํ๋ฆ | -9.32์ต | -51.19% |
์์ฌ ํ๊ธ ํ๋ฆ | -12.36์ต | -199.38% |
์ ๋ณด
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgรฅrd, Denmark and Thรถrishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development. Wikipedia
์ค๋ฆฝ
1992. 7. 1.
์น์ฌ์ดํธ
์ง์ ์
1,645
